Breaking News


Cereplast Reports Financial Results for the First Nine Months of 2013

Cereplast Reports Financial Results for the First Nine Months of 2013  SEYMOUR, Ind., Nov. 14, 2013 (GLOBE NEWSWIRE) -- Cereplast, Inc. (OTCQB:CERP) (the "Company"), a leading manufacturer of proprietary biobased, compostable and sustainable bioplastics, today announced $2.1 million in revenue during the first nine months of 2013 compared to $786,000 for the same period the prior year and a total of $911,000 for the 2012 full year.  Cereplast Chairman and Chief Executive Officer Mr. Frederic Scheer stated, "We are pleased with the year-over-year growth we have experienced for the first nine months of 2013 and we expect to continue this trend as the global market opportunity continues to increase. The most immediate growth driver is the ongoing legislation in Italy for the sanctions of traditional plastic bags. We continue to work closely with customers who are capable of placing orders much larger than they are today in the anticipation of the ruling."  Mr. Scheer continued, "Italy and subsequent European countries have created an immense opportunity for us but we are not putting all of our eggs in one basket. We foresee India and the United States as significant markets for us as well. Both markets are already enforcing sanctions in select areas. We have feet on the ground in each market and are beginning to secure contracts by first educating the marketplace about the benefits of our technology. In India we recently received a $1.4 million order and in the U.S. we are actively pursuing 30 projects with a potential value of over $10 million per year. We anticipate continued traction in both markets."  2013 Industry, Financial and Operational Highlights to Date:    oRevenue for the first nine months of 2013 totaled $2.1 million.   oIn a recent document, the European Union Environmental Commission stated     that they are in support of an amendment to this legislation, which is     scheduled to go into effect in November and member states will have two     years to comply.   oCereplast has estimated annual revenue potential from Italy alone to     exceed $50 million.   oFor the past 18 months, the Company has worked closely with over 70     companies in Italy that have completed multiple successful tests with     various grades of their blown film resins.   oIn India, Cereplast recently received a $1.4 million purchase order, which     will ship over the next 10 months.   oAdditionally, Cereplast received five purchase orders in India totaling     $450,000 for blown film resins which will be delivered throughout the     remainder of 2013.   oIn the United States, regional and federal laws are supporting growth of     the bioplastics industry as seen by movements in San Francisco, Portland     and New York City.   oCereplast has valued the bioplastic industry in the United States today to     be $180 million and expects to begin generating meaningful revenue in     2014.   oCereplast is actively pursuing 30 projects in North America with potential     value of $10 million per year.   oCereplast recently launched reVive™ bioplastic resins, the first     bioplastics to combine recycled polymers with biobased resins for improved     sustainability, reducing the carbon footprint of this type of bioplastic     by adding the environmental benefits of recycled plastic.  2013 First Nine Months Financial Results:  Net sales for the nine months ended September 30, 2013 were approximately $2.1 million, compared to $0.8 million in the same period in 2012. Sales increased from the prior year due to growing demand in European markets primarily due to anticipated legislation in Italy banning traditional plastic bags.  Cost of sales is comprised of variable costs associated with product revenues. Cost of sales for the nine months ended September 30, 2013 was approximately $1.9 million, compared to $0.9 million for the same period in 2012. The increase in cost of sales is due to an increase in sales.  Gross profit (loss) for the nine months ended September 30, 2013 was approximately $0.3 million, compared to ($0.1) million for the same period in 2012. The increase in gross profit was attributable to an increase in sales, as stated above.  Research and development expenses for the nine months ended September 30, 2013 were $0.3 million, compared to approximately $0.4 million for the same period in 2012. Research and development expenses have slightly decreased due to a cost containment effort to preserve working capital.  Selling, general and administrative expenses for the nine months ended September 30, 2013 were $3.8 million, compared to $10.5 million for the same period in 2012. The decrease in sales, general and administrative expenses was primarily due to bad debt expense of $5.1 million recorded in the third quarter of 2013. In addition, the sales, general and administrative expenses decreased due to reduced headcount and a reduction in fixed production overhead costs classified as selling, general and administrative expense due to an extended period of abnormally low production volume.  Other income and expense, net for the nine months ended September 30, 2013 was a net expense of $29.6 million, as compared to a net expense of $5.3 million in the same period in 2012. The increase in expense was primarily a result of the change in our derivative liability related to our warrants, short-term convertible debt and preferred stock agreements. In addition, we recorded $2.8 million in debt extinguishment costs related to the exchange of certain of our term loan and convertible notes.  Net loss for the nine months ended September 30, 2013 was $34 million, as compared to $16.3 million in the same period in 2012. The increase in net loss was primarily driven by an increase in Other Expense related to financing transactions. As discussed above, Other Income and Expense, net was unfavorably impacted by losses on derivative liabilities totaling $21.6 million. The increase in net loss was partially offset by a decrease in bad debt expense recorded in the first nine months of 2013 compared to the first nine months of 2012.  Conference Call        Details: Date:                 Thursday, November 14^th Time:                 4:30 p.m. Eastern Participant Dial-In:  (480) 629-9761 Live Webcast:  It is recommended that participants dial in approximately 10 minutes prior to the start of the 4:30 p.m. Eastern call. There will also be a simultaneous live webcast of the conference call which can be accessed through the following audio feed link and archived recording of the conference call available under the Investor Relations section of the company website at  About Cereplast, Inc.  Cereplast, Inc. (OTCQB:CERP) designs and manufactures proprietary biobased, sustainable bioplastics which are used as substitutes for traditional plastics in all major converting processes - such as injection molding, thermoforming, blow molding and extrusions - at a pricing structure that is competitive with traditional plastics. On the cutting-edge of biobased plastic material development, Cereplast now offers resins to meet a variety of customer demands. Cereplast Compostables® resins are ideally suited for single-use applications where high biobased content and compostability are advantageous, especially in the food service industry. Cereplast Sustainables® resins combine high biobased content with the durability and endurance of traditional plastic, making them ideal for applications in industries such as automotive, consumer electronics and packaging. Learn more at You may also visit the Cereplast social networking pages at, and  Safe Harbor Statement  Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.  CEREPLAST, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except shares data)                                                                                                                September 30, 2013 December 31,                                                                   2012                                               (Unaudited) ASSETS                                                            Current Assets                                                    Cash                                           $233             $183 Accounts Receivable, Net                       1,021              149 Inventory, Net                                 5,722              6,941 Prepaid Expenses and Other Current Assets      199               227 Total Current Assets                           7,175              7,500                                                                  Property and Equipment                                            Property and Equipment                         11,152             11,601 Accumulated Depreciation and Amortization      (4,660)            (4,004) Property and Equipment, Net                    6,492              7,597                                                                  Other Assets                                                      Restricted Cash                                --               43 Deferred Loan Costs                            350               750 Intangible Assets, Net                         239                245 Deposits                                       48                 47 Total Other Assets                             637                1,085                                                                  Total Assets                                   $14,304          $16,182                                                                  LIABILITIES AND SHAREHOLDERS' DEFICIT                             Current Liabilities                                               Accounts Payable                               $920             $803 Accrued Expenses                               3,386              3,663 Capital Leases, Current Portion                97                 85 Loan Payable, Current Portion                  6,224              5,978 Convertible Subordinated Notes, Current        1,122              891 Portion Derivative Liability                           15,142             3,189 Preferred Stock, $0.001 par value; 5,000,000 shares authorized; 490 and 92 sharesissued    2,213             500 and outstanding at September 30, 2013 and December 31, 2012, respectively Total Current Liabilities                      29,104             15,109                                                                  Long-Term Liabilities                                             Loan Payable                                   --                923 Convertible Subordinated Notes                 7,500             10,000 Capital Leases, Long-Term                      120               173 Total Long-Term Liabilities                    7,620              11,096 Total Liabilities                              36,724             26,205                                                                  Shareholders' Deficit                                             Common Stock, $0.001 par value; 2,000,000,000 shares authorized;810,757,671 and 63,463,659  811               63 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively Common Stock Subscribed, not issued            1,358             -- Additional Paid in Capital                     96,416            76,919 Accumulated Deficit                            (121,136)         (87,097) Accumulated Other Comprehensive Income         127               88                                               (22,424)          (10,027) Noncontrolling Interests                       4                 4 Total Shareholders' Deficit                    (22,420)           (10,023) Total Liabilities and Shareholders' Deficit    $14,304          $16,182    CEREPLAST, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME (unaudited, in thousands, except per share data)                                                                                     Three Months Ended        Nine Months Ended                       September 30, September 30, September 30, September 30,                        2013          2012          2013          2012                                                               Gross Product Sales    $438        $481        $2,135      $786 Sales Discounts,       (2)          (4)          (3)          (16) Returns and Allowances Net Sales              436          477          2,132        770                                                               Cost of Goods Sold     382          473          1,880        861 Gross Profit (Loss)    54           4            252          (91)                                                               Operating Expenses:                                            Research and           75           115          295          370 Development Selling, General and   1,134        6,847        3,796        10,519 Administrative Impairment of          547          --           547          -- Long-Lived Assets Total Operating        1,756        6,962        4,638        10,889 Expenses Operating Loss         (1,702)      (6,958)      (4,386)      (10,980)                                                               Debt Extinguishment    (1,065)      --           (2,821)      (427) Costs Change in Derivative   (2,392)      47           (21,629)     (52) Liabilities Interest and Other     --           --           --           18 Income Interest Expense       (2,112)      (3,057)      (5,203)      (4,834) Loss Before Provision  (7,271)      (9,968)      (34,039)     (16,275) for Income Taxes Provision for Income   --           --           --           -- Taxes Net Loss               $(7,271)    $(9,968)    $(34,039)   $(16,275)                                                                                                                             Net Loss Per Share -   $(0.01)     $(0.40)     $(0.07)     $(0.77) Basic and Diluted                                                               Weighted Average Common Shares          731,817,081  24,739,449   482,042,209  21,242,115 Outstanding - Basic and Diluted    CEREPLAST, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited, in thousands, except shares data)                                                                                                     Nine Months Ended                                         September 30, 2013 September 30, 2012                                                            CASH FLOWS FROM OPERATING ACTIVITIES:                       Net Loss                                 $(34,039)        $(16,275) Adjustment to Reconcile Net Loss to Net                     Cash Used in Operating Activities Depreciation and Amortization            665               536 Allowance for Doubtful Accounts          3                 5,082 Common Stock Issued for Services,        171               160 Salaries and Wages Amortization of Loan Discount            4,230             3,223 Extinguishment of Convertible Debt       2,821             368 Loss on Derivative Liabilities           21,629            52 Impairment of Long-Lived Assets          547               -- Changes in Operating Assets and                             Liabilities Accounts Receivable                      (875)             537 Deferred Loan Costs                      400               458 Inventory                                1,219             814 Prepaid Expenses                         28                (171) Restricted Cash                          43                -- Accounts Payable                         116               659 Accrued Expenses                         749               288 NET CASH USED IN OPERATING ACTIVITIES    (2,293)           (4,269)                                                            CASH FLOWS FROM INVESTING ACTIVITIES:                       Purchase of Property and Equipment, and  (3)               (180) Intangibles Proceeds from Sale of Equipment          --                15 NET CASH USED IN INVESTING ACTIVITIES    (3)               (165)                                                            CASH FLOWS FROM FINANCING ACTIVITIES:                       Payments on Capital Leases               (41)              (50) Payments made on Notes Payable           (63)              (603) Proceeds from Convertible Notes, Net of  63                600 Issuance Costs Proceeds from Issuance of Preferred      2,750             400 Stock Proceeds from Issuance of Common Stock   (23)              400 and Subscriptions, Net of Issuance Costs NET CASH PROVIDED BY FINANCING           2,686             747 ACTIVITIES                                                            FOREIGN CURRENCY TRANSLATION             (340)             (16)                                                            NET INCREASE (DECREASE) IN CASH          50                 (3,703)                                                            CASH AND CASH EQUIVALENTS, BEGINNING OF  183               3,940 PERIOD CASH AND CASH EQUIVALENTS, END OF PERIOD $233             $237  CONTACT: Cereplast, Inc.          Public Relations          Nicole Robertson          812.220.5400 X1013                   Investor Relations:          Alliance Advisors, LLC          Valter Pinto          914-669-0222 x201  Cereplast, Inc. Logo